Risk Summary
Based on findings from animal reproduction studies, ZAVESCA may cause fetal harm when administered to a pregnant woman. Available data from postmarketing case reports with ZAVESCA use in pregnancy are insufficient to assess a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks associated with symptomatic Type I Gaucher disease in pregnancy, including hepatosplenomegaly and thrombocytopenia
(see
Clinical Considerations).
Advise pregnant women of the potential risks to the fetus.
In animal reproduction studies, miglustat was maternally toxic in rabbits at exposures near the expected human therapeutic dose and caused embryo-fetal toxicities in rats at doses twice the recommended human dose. No adverse developmental outcomes were observed with administration of miglustat to pregnant rats at dose levels 6 times the recommended human dose.
(see
Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.
Clinical Considerations
Disease-associated Maternal and Embryo-Fetal Risk
Pregnancy may exacerbate existing Type 1 Gaucher disease symptoms or result in new disease manifestations. Type 1 Gaucher disease manifestations may lead to adverse pregnancy outcomes including, hepatosplenomegaly which can interfere with the normal growth of a pregnancy and thrombocytopenia which can lead to increased bleeding and possible hemorrhage.
Data
Animal Data
In female rats given miglustat by oral gavage at doses of 20, 60, 180 mg/kg/day beginning 14 days before mating and continuing through gestation day 17 (organogenesis), increased post implantation loss, decreased embryo-fetal survival and decreased fetal and pup weights were observed at doses ≥60 mg/kg/day (≥2 times the human therapeutic dose on a mg/m
2 basis). Miglustat was also administered to pregnant rats by oral gavage at doses of 20, 60, 180 mg/kg/day from gestation day 6 through lactation (postpartum day 20). Delayed and prolonged parturition with decreased live births were observed at doses ≥60 mg/kg/day (≥2 times the human therapeutic dose on a mg/m
2 basis).
In pregnant rabbits given miglustat by oral gavage at doses of 15, 30, 45 mg/kg/day during gestation days 6–18 (organogenesis), maternal toxicity, including maternal deaths (all doses), reduced food consumption (30 and 45 mg/kg/day), and decreased body weight gain (15 and 30 mg/kg/day), was observed. The 15 mg/kg/day dose level was 0.97 times the human therapeutic dose on a mg/m
2 basis.
In a pre- and postnatal development study in rats, miglustat was administered by oral gavage at doses of 20, 60, 180 mg/kg/day from gestation day 6 through day 20 of lactation, decreased live births were observed in dams, as well as decreased body weight gain in the offspring at doses ≥60 mg/kg/day (≥2 times the human therapeutic dose on a mg/m
2 basis). There was no effect on behavioral and learning assessments, sexual maturation or reproductive performance of the offspring at doses up to 180 mg/kg/day (about 6 times the human therapeutic dose on a mg/m
2 basis).
Risk Summary
There are no available data on the presence of miglustat in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. Based on the physical properties of miglustat, ZAVESCA is likely to be present in breast milk. Because of the potential for serious adverse reactions in breastfed infants, advise women that breastfeeding is not recommended.
Infertility
Findings from a small clinical study in seven healthy adult males who received miglustat for six weeks did not indicate effects on male fertility. Studies in male rats have shown that miglustat decreased fertility but findings were reversible. Studies in female rats have shown increased post-implantation loss and decreased embryo-fetal survival
[see
Use in Specific Populations (8.1),
Nonclinical Toxicology (13.1)]
.
Absorption
After a 100 mg oral dose, the time to maximum observed plasma concentration of miglustat (t
max) ranged from 2 to 2.5 hours in Gaucher patients. Plasma concentrations show a biexponential decline, characterized by a short distribution phase and a longer elimination phase. The effective half-life of miglustat is approximately 6 to 7 hours, which predicts that steady-state will be achieved by 1.5 to 2 days following the start of three times daily dosing.
Miglustat, dosed at 50 and 100 mg three times daily in Gaucher patients, exhibits dose-proportional pharmacokinetics. The pharmacokinetics of miglustat were not altered after repeated dosing three times daily for up to 12 months.
In healthy subjects, co-administration of ZAVESCA with food results in a decrease in the rate of absorption of miglustat (maximum plasma concentration [C
max] was decreased by 36% and t
max delayed 2 h) but had no statistically significant effect on the extent of absorption of miglustat (area-under-the-plasma-concentration time curve [AUC] was decreased by 14%). The mean oral bioavailability of a 100-mg miglustat capsule is about 97% relative to an oral solution administered under fasting conditions. The pharmacokinetics of miglustat were similar between adult type 1 Gaucher disease patients and healthy subjects after a single dose administration of miglustat 100 mg.
Distribution
Miglustat does not bind to plasma proteins. Mean apparent volume of distribution of miglustat is 83–105 liters in Gaucher patients. At steady state, the concentration of miglustat in cerebrospinal fluid of six non-Gaucher patients was 31.4–67.2% of that in plasma, indicating that miglustat crosses the blood brain barrier.
Metabolism and Excretion
The major route of excretion of miglustat is via kidney. Following administration of a single dose of 100 mg
14C-miglustat to healthy volunteers, 83% of the radioactivity was recovered in urine and 12% in feces. In healthy subjects, 67% of the administered dose was excreted unchanged in urine over 72 hours. The most abundant metabolite in urine was miglustat glucuronide accounting for 5% of the dose. The terminal half-life of radioactivity in plasma was 150 hours, suggesting the presence of one or more metabolites with a prolonged half-life. The metabolite accounting for this observation has not been identified, but may accumulate and reach concentrations exceeding those of miglustat at steady state.
Specific Populations
Gender
There was no statistically significant gender difference in miglustat pharmacokinetics, based on pooled data analysis.
Race
Ethnic differences in miglustat pharmacokinetics have not been evaluated in Gaucher patients. However, apparent oral clearance of miglustat in patients of Ashkenazi Jewish descent was not statistically different to that in others (1 Asian and 15 Caucasians), based on a cross-study analysis.
Hepatic Impairment
No studies have been performed to assess the pharmacokinetics of miglustat in patients with hepatic impairment.
Renal Impairment
Limited data in non-Gaucher patients with impaired renal function indicate that the apparent oral clearance (CL/F) of miglustat decreases with decreasing renal function. While the number of subjects with mild and moderate renal impairment was very small, the data suggest an approximate decrease in the apparent oral clearance of 40% and 60% respectively, in mild and moderate renal impairment, justifying the need to decrease the dosing of miglustat in such patients dependent upon creatinine clearance levels
[see
Dosage and Administration (2.2)].
Data in severe renal impairment are limited to two patients with creatinine clearances in the range 18–29 mL/min and cannot be extrapolated below this range. These data suggest a decrease in CL/F by at least 70% in patients with severe renal impairment
[see
Dosage and Administration (2.2) and
Use in Specific Populations (8.6)].
Drug Interaction Studies
Miglustat does not inhibit the metabolism of various substrates of cytochrome P450 enzymes including, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A11
in vitro; consequently, significant interactions via inhibition of these enzymes are unlikely with drugs that are substrates of cytochrome P450 enzymes.
Drug interaction between ZAVESCA (miglustat 100 mg orally three times daily) and imiglucerase 7.5 or 15 U/kg/day was assessed in imiglucerase-stabilized patients after one month of co-administration. There was no significant effect of imiglucerase on the pharmacokinetics of miglustat, with the co-administration of imiglucerase and miglustat resulting in a 22% reduction in C
max and a 14% reduction in the AUC for miglustat. While ZAVESCA appeared to increase the clearance of imiglucerase by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of imiglucerase
[see
Drug Interactions (7)].
Concomitant therapy with loperamide during clinical trials did not appear to significantly alter the pharmacokinetics of miglustat.
Carcinogenesis
Two-year carcinogenicity studies have been conducted with miglustat in CD-1 mice at oral doses up to 500 mg/kg/day and in Sprague Dawley rats at oral doses up to 180 mg/kg/day. Oral administration of miglustat for 104 weeks produced mucinous adenocarcinomas of the large intestine at 210, 420 and 500 mg/kg/day (about 3, 6 and 7 times the recommended human dose, respectively, based on the body surface area) in male mice and at 420 and 500 mg/kg/day (about 6 and 7 times the recommended human dose, based on the body surface area) in female mice. The adenocarcinomas were considered rare in CD-1 mice and occurred in the presence of inflammatory and hyperplastic lesions in the large intestine of both males and females. In rats, oral administration of miglustat for 100 weeks produced increased incidences of interstitial cell adenomas of the testis at 30, 60 and 180 mg/kg/day (about 1, 2 and 5 times the recommended human dose, respectively, based on the body surface area).
Mutagenesis
Miglustat was not mutagenic or clastogenic in a battery of
in vitro and
in vivo assays including the bacterial reverse mutation (Ames), chromosomal aberration (in human lymphocytes), gene mutation in mammalian cells (Chinese hamster ovary), and mouse micronucleus assays.
Impairment of Fertility
Miglustat was administered by oral gavage to male rats at doses of 20, 60, 180 mg/kg/day beginning at least 14 days prior to mating and continuing through mating. Effects on sperm parameters (concentration, motility and morphology) resulting in decreased fertility were observed at all dose levels (the lowest dose level was 0.65 times the human therapeutic dose on a mg/m
2 basis). Reversibility was demonstrated following 6 weeks of drug withdrawal. Findings of, seminiferous tubule degeneration and atrophy were observed in the testes in rat repeat-dose toxicity studies.
Miglustat was administered by oral gavage to female rats at doses of 20, 60, 180 mg/kg/day beginning 14 days before mating and continuing through gestation day 17. There were no effects on mating performance or fertility in female rats at doses up to 180 mg/kg/day. However, increased post implantation loss and decreased embryo-fetal survival were observed at doses ≥60 mg/kg/day (≥2 times the human therapeutic dose on a mg/m
2 basis).
Open-Label Uncontrolled Monotherapy Trials
In Study 1, ZAVESCA was administered at a starting dose of 100 mg three times daily for 12 months (dose range of 100 once-daily to 200 mg three times daily) to 28 adult patients with type 1 Gaucher disease, who were unable to receive enzyme replacement therapy and who had not taken enzyme replacement therapy in the preceding 6 months. Twenty-two patients completed the trial. After 12 months of treatment, the results showed significant mean percent reductions from baseline in liver volume of 12% and spleen volume of 19%, a non-significant increase from baseline in mean absolute hemoglobin concentration of 0.26 g/dL and a mean absolute increase from baseline in platelet counts of 8×10
9/L (See Tables 3–6).
In Study 2, ZAVESCA was administered at a dose of 50 mg three times daily for 6 months to 18 adult patients with type 1 Gaucher disease who were unable to receive enzyme replacement therapy and who had not taken enzyme replacement therapy in the preceding 6 months. Seventeen patients completed the trial. After 6 months of treatment, the results showed significant mean percent reductions from baseline in liver volume of 6% and spleen volume of 5%. There was a non-significant mean absolute decrease from baseline in hemoglobin concentration of 0.13 g/dL and a non-significant mean absolute increase from baseline in platelet counts of 5×10
9/L (See Tables 3–6).
Extension Period
Eighteen patients were enrolled in a 12-month extension to Study 1. A subset of patients continuing in the extension had larger mean baseline liver volumes, and lower mean baseline platelet counts and hemoglobin concentrations than the original study population (See Tables 3–6). After a total of 24 months of treatment, there were significant mean decreases from baseline in liver and spleen organ volumes of 15% and 27%, respectively, and significant mean absolute increases from baseline in hemoglobin concentration and platelet count of 0.9 g/dL and 14×10
9/L, respectively (See Tables 3–6).
Sixteen patients were enrolled in a 6-month extension to Study 2. After a total of 12 months of treatment, there was a mean decrease from baseline in spleen organ volume of 10%, whereas the mean percent decrease in liver organ volume remained at 6%. There were no significant changes in hemoglobin concentrations or platelet counts (See Tables 3–6).
Liver volume results from Studies 1 and 2 and their extensions are summarized in Table 3:
Table 3: Liver Volume Changes in Two Open-Label Uncontrolled Monotherapy Trials of ZAVESCA with Extension Period | | Liver Volume |
|---|
| n | Absolute Mean (L)
(2-sided 95% CI)
| Percent Mean (%)
(2-sided 95% CI)
|
|---|
| Study 1 (starting dose ZAVESCA 100 mg three times daily) |
| Baseline (Month 0) | 21 | 2.39 | |
| Month 12 Change from baseline | | -0.28 (-0.38, -0.18) | -12.1% (-16.4, 7.9) |
| Study 1 Extension Phase |
| Baseline (Month 0) | 12 | 2.54 | |
| Month 24 Change from baseline | | -0.36 (-0.48, -0.24) | -14.5% (-19.3, 9.7) |
| Study 2 (ZAVESCA 50 mg three times daily) |
| Baseline (Month 0) | 17 | 2.45 | |
| Month 6 Change from baseline | | -0.14 (-0.25, -0.03) | -5.9% (-9.9, -1.9) |
| Study 2 Extension Phase |
| Baseline (Month 0) | 13 | 2.35 | |
| Month 12 Change from baseline | | -0.17 (-0.3, -0.0) | -6.2% (-12.0, -0.5) |
Spleen volume results from Studies 1 and 2 and their extensions are summarized in Table 4:
Table 4: Spleen Volume Changes in Two Open-Label Uncontrolled Monotherapy Trials of ZAVESCA with Extension Period | | Spleen Volume |
|---|
| n | Absolute Mean (L)
(2-sided 95% CI)
| Percent Mean (%)
(2-sided 95% CI)
|
|---|
| Study 1 (starting dose ZAVESCA 100 mg three times daily) |
| Baseline (Month 0) | 18 | 1.64 | |
| Month 12 Change from baseline | | -0.32 (-0.42, -0.22) | -19.0% (-23.7, -14.3) |
| Study 1 Extension Phase |
| Baseline (Month 0) | 10 | 1.56 | |
| Month 24 Change from baseline | | -0.42 (-0.53, -0.30) | -26.4% (-30.4, -22.4) |
| Study 2 (ZAVESCA 50 mg three times daily) |
| Baseline (Month 0) | 11 | 1.98 | |
| Month 6 Change from baseline | | -0.09 (-0.18, -0.01) | -4.5% (-8.2, -0.7) |
| Study 2 Extension Phase |
| Baseline (Month 0) | 9 | 1.98 | |
| Month 12 Change from baseline | | -0.23 (-0.46, 0.00) | -10.1% (-20.1, -0.1) |
Hemoglobin concentration results from Studies 1 and 2 and their extensions are summarized in Table 5:
Table 5: Hemoglobin Concentration Changes in Two Open-Label Uncontrolled Monotherapy Trials of ZAVESCA with Extension Period | | Hemoglobin Concentration |
|---|
| n | Absolute Mean (g/dL)
(2-sided 95% CI)
| Percent Mean (%)
(2-sided 95% CI)
|
|---|
| Study 1 (starting dose ZAVESCA 100 mg three times daily) |
| Baseline (Month 0) | 22 | 11.94 | |
| Month 12 Change from baseline | | 0.26 (-0.05, 0.57) | 2.6% (-0.5, 5.7) |
| Study 1 Extension Phase |
| Baseline (Month 0) | 13 | 11.03 | |
| Month 24 Change from baseline | | 0.91 (0.30, 1.53) | 9.1% (2.9, 15.2) |
| Study 2 (ZAVESCA 50 mg three times daily) |
| Baseline (Month 0) | 17 | 11.60 | |
| Month 6 Change from baseline | | -0.13 (-0.51, 0.24) | -1.3% (-4.4, 1.8) |
| Study 2 Extension Phase |
| Baseline (Month 0) | 13 | 11.94 | |
| Month 12 Change from baseline | | 0.06 (-0.73, 0.85) | 1.2% (-5.2, 7.7) |
Platelet count results from Studies 1 and 2 and their extensions are summarized in Table 6:
Table 6: Platelet Count Changes in Two Open-Label Uncontrolled Monotherapy Trials of ZAVESCA with Extension Period | | Platelet Count |
|---|
| n | Absolute Mean (10
9/L)
(2-sided 95% CI)
| Percent Mean (%)
(2-sided 95% CI)
|
|---|
| Study 1 (starting dose ZAVESCA 100 mg three times daily) |
| Baseline (Month 0) | 22 | 76.58 | |
| Month 12 Change from baseline | | 8.28 (1.88, 14.69) | 16.0% (-0.8, 32.8) |
| Study 1 Extension Phase |
| Baseline (Month 0) | 13 | 72.35 | |
| Month 24 Change from baseline | | 13.58 (7.72, 19.43) | 26.1% (14.7, 37.5) |
| Study 2 (ZAVESCA 50 mg three times daily) |
| Baseline (Month 0) | 17 | 116.47 | |
| Month 6 Change from baseline | | 5.35 (-6.31, 17.02) | 2.0% (-6.9, 10.8) |
| Study 2 Extension Phase |
| Baseline (Month 0) | 13 | 122.15 | |
| Month 12 Change from baseline | | 14.0 (-3.4, 31.4) | 14.7% (-1.4, 30.7) |
Open-Label Active-Controlled Trial
Study 3 was an open-label, randomized, active-controlled study of 36 adult patients with type 1 Gaucher disease, who had been receiving enzyme replacement therapy with imiglucerase for a minimum of 2 years prior to study entry. Patients were randomized 1:1:1 to one of three treatment groups, as follows:
- ZAVESCA 100 mg three times daily alone
- imiglucerase (patient's usual dose) alone
- ZAVESCA 100 mg three times daily and imiglucerase (usual dose)
Patients were treated for 6 months, and 33 patients completed the study. Because ZAVESCA is only indicated as monotherapy, the results for the monotherapy arms are described below. At Month 6, the results showed a decrease in mean percent change in liver volume in the ZAVESCA treatment group compared to the imiglucerase alone group. There were no significant differences between the groups for mean absolute changes in liver and spleen volume and hemoglobin concentration. However, there was a significant difference between the ZAVESCA alone and imiglucerase alone groups in platelet counts at Month 6, with the ZAVESCA alone group having a mean absolute decrease in platelet count of 21.6×10
9/L and the imiglucerase alone group having a mean absolute increase in platelet count of 10.1×10
9/L (See Tables 7–10).
Extension period
Twenty-nine patients were enrolled in a 6-month extension to Study 3. In the extension phase, all 29 patients had withdrawn from imiglucerase and received open-label ZAVESCA 100 mg three times daily monotherapy. At Month 12, the results showed non-significant decreases in platelet counts from baseline in all the treatment groups (by original randomization). There was a significant decrease in platelet counts from Month 6 to Month 12 in the group originally randomized to treatment with imiglucerase, and a continued decrease in platelet counts in the group originally randomized to ZAVESCA alone. There were no significant changes in any treatment group for liver volume, spleen volume, or hemoglobin concentration (See Tables 7–10).
Liver volume results from Study 3 and extension are summarized in Table 7:
Table 7: Liver Volume Changes from Study 3 and Extension Phase | Imiglucerase alone | ZAVESCA alone |
|---|
| Study 3 | n=11 | n=10 |
| Month 0 | 1.81 | 1.58 |
| Month 6 Change (L) | 0.04 | -0.05 |
| Month 6 % Change | 3.6% | -2.9% |
| Adjusted mean Difference from Imiglucerase (95% CI) | | -4.5% (-13.2, 4.2) |
| Extension Phase
All patients received ZAVESCA 100 mg three times daily monotherapy from Month 6 to Month 12. | n=10 | n=8 |
| Month 0 | 1.94 | 1.60 |
| Month 12 Change (L) | -0.05 | -0.01 |
| Month 12 % Change | -0.7% | -0.8% |
Spleen volume results from Study 3 and extension are summarized in Table 8:
Table 8: Spleen Volume Changes from Study 3 and Extension Phase | Imiglucerase alone | ZAVESCA alone |
|---|
| Study 3 | n=8 | n=7 |
| Month 0 | 0.61 | 0.69 |
| Month 6 Change (L) | -0.02 | -0.03 |
| Month 6 % Change | -2.1% | -4.8% |
| Adjusted % Difference from Imiglucerase (95% CI) | | -5.8% (-22.1, 10.5) |
| Extension Phase
All patients received ZAVESCA 100 mg three times daily monotherapy from Month 6 to Month 12. | n=7 | n=6 |
| Month 0 | 0.83 | 0.57 |
| Month 12 Change (L) | 0.04 | -0.05 |
| Month 12 % Change | 1.5% | -6.1% |
Hemoglobin concentration results from Study 3 and extension are summarized in Table 9:
Table 9: Hemoglobin Concentration Changes from Study 3 and Extension Phase | Imiglucerase alone | ZAVESCA alone |
|---|
| Study 3 | n=12 | n=10 |
| Month 0 | 13.18 | 12.44 |
| Month 6 Change (g/dL) | -0.15 | -0.31 |
| Month 6 % Change | -1.2% | -2.4% |
| Adjusted % Difference from Imiglucerase (95% CI) | | -1.9% (-6.4, 2.6) |
| Extension Phase
All patients received ZAVESCA 100 mg three times daily monotherapy from Month 6 to Month 12 . | n=10 | n=9 |
| Month 0 | 13.39 | 12.46 |
| Month 12 Change (g/dL) | -0.48 | -0.13 |
| Month 12 % Change | -3.1% | -1.1% |
Platelet count results from Study 3 and extension are summarized in Table 10:
Table 10: Platelet Count Changes from Study 3 and Extension Phase | Imiglucerase alone | ZAVESCA alone |
|---|
| Study 3 | n=12 | n=10 |
| Month 0 | 165.75 | 170.55 |
| Month 6 Change (10
9/L)
| 15.29 | -21.60 |
| Month 6 % Change | 10.1% | -9.6% |
| Adjusted % Difference from Imiglucerase (95% CI) | | -17.1% (-32.9, -1.3) |
| Extension Phase
All patients received ZAVESCA 100 mg three times daily monotherapy from Month 6 to Month 12. | n=10 | n=9 |
| Month 0 | 170.05 | 184.83 |
| Month 12 Change (10
9/L)
| -3.75 | -27.39 |
| Month 12 % Change | -3.2% | -10.4% |
Patients with platelet counts above 150 × 10
9/L at baseline who were randomized to ZAVESCA treatment had significant decreases in platelet counts at Month 12.
Information for Patients
- Advise patients that the most common serious adverse reaction reported with ZAVESCA is peripheral neuropathy. Advise patients to promptly report any numbness, tingling, pain, or burning in the hands and feet
[see
Warnings and Precautions (5.1)]
.
- Advise patients that other adverse reactions include tremor and reductions in platelet counts. Advise patients to promptly report the development of tremor or worsening in an existing tremor
[see
Warnings and Precautions (5.2,
5.4)].
- Advise patients that other serious adverse reactions include diarrhea and weight loss. Advise patients to adhere to dietary instructions
[see
Warnings and Precautions (5.3)]
.
- Advise patients to take the next ZAVESCA capsule at the next scheduled time if a dose is missed.
- Inform patients of the potential risks and benefits of ZAVESCA and of alternative modes of therapy.
Pregnancy
Advise pregnant women and females of reproductive potential of the potential risk to a fetus, based on animal data. Advise patients who may become pregnant to inform their healthcare provider of a known or suspected pregnancy
[see
Use in Specific Populations (8.1)].
Lactation
Advise women not to breastfeed if they are taking ZAVESCA
[see
Use in Specific Populations (8.2)].
Manufactured for:
Actelion Pharmaceuticals US, Inc.,
a Janssen Pharmaceutical Company
Titusville, NJ 08560, USA
© 2003 – 2017 Actelion Pharmaceuticals US, Inc.
JN20220808